Search results for: Health Data and Statistics
Filter search results
New Publication: Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers
25 September 2015
…health outcomes-based RSAs. The authors explain that utilisation of RSAs could increase as data systems improve and incentives evolve as a result of health reform and accountable care organisations. Access…
Government and Charity Funding of Cancer Research: Public Preferences and Choices
13 October 2015
…as an OHE Research Paper. Reference: Shah, K.K., Sussex, J. and Hernandez-Villafuerte, K., 2015. Government and charity funding of cancer research: public preferences and choices. Health Research Policy and Systems,…
Just Published: Testing the Feasibility of Obtaining EQ-5D-5L Values in the United Arab Emirates
23 October 2015
…feasibility and cultural appropriateness of stated preference methods to generate health state values in the United Arab Emirates. Value in Health Regional Issues, 7C, pp.34-41. Access the paper here. Click…
New OHE Research Paper: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
3 May 2016
…for Health and Care Excellence (NICE). The research was undertaken by Emma Brockis, MSc placement student, in collaboration with OHE’s Grace Marsden, Amanda Cole, and Professor Nancy Devlin. NICE’s decisions…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
…to) payers, PAGs, regulators, health data scientists, academics and industry. This is an AstraZeneca organised and funded non–promotional meeting facilitated by OHE. Veeva ID: Z4-65649 Date of preparation: June 2024…
An Insurance Framework for Funding New Antibiotics
22 September 2017
…premium price model is familiar and readily implemented but the required price and local budget impact are both highly uncertain and sensitive to cross-sectional and longitudinal variation in prevalence of…
Open Access Week 2017: Open in Order To…
25 October 2017
…inform better decision-making in the context of health and health care. Our treasure trove of historical work dates back to October 1962, when the field of health economics was just…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…data exclusivity (DE), and Supplementary Protection Certificates (SPCs), is seen as important. This is due to the high cost of research and development (R&D) for new medicines and the issue…
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
…for the English National Health Service (NHS) for the same period at 8.0%. However, NHS Digital reported much-reduced medicines expenditure growth for England of 3.5% for 2016/17, suggesting a complex…